StockData
Zymeworks Inc. logo

Zymeworks Inc. (ZYME) stock

ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30667% above fair value
$25.84−0.61 (-2.31%)

Close on Nov 17, 2026Market cap $1.83BP/E –Yield –

Zymeworks operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Zymeworks's operating income for the twelve months ending Jun 30, 2026 was -$155.56M. For fiscal 2025 it was -$92.55M. The highest annual figure on record is $130.53M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$92.55M–
FY2024Dec 31, 2024-$137.11M–
FY2023Dec 31, 2023-$138.05M-205.8%
FY2022Dec 31, 2022$130.53M–
FY2021Dec 31, 2021-$215.63M–
FY2020Dec 31, 2020-$187.47M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$42.18M–
Q1 FY2026Mar 31, 2026-$47.12M–
Q4 FY2025Dec 31, 2025-$44.15M–
Q3 FY2025Sep 30, 2025-$22.11M–
Q2 FY2025Jun 30, 2025-$674.00K–
Q1 FY2025Mar 31, 2025-$25.61M–
Q4 FY2024Dec 31, 2024-$22.22M–
Q3 FY2024Sep 30, 2024-$34.21M–
Q2 FY2024Jun 30, 2024-$42.89M–
Q1 FY2024Mar 31, 2024-$37.80M–
Q4 FY2023Dec 31, 2023-$23.42M-107.3%
Q3 FY2023Sep 30, 2023-$33.24M–
Q2 FY2023Jun 30, 2023-$54.11M–
Q1 FY2023Mar 31, 2023-$27.28M–
Q4 FY2022Dec 31, 2022$319.40M–
Q3 FY2022Sep 30, 2022-$50.36M–
Q2 FY2022Jun 30, 2022-$65.82M–
Q1 FY2022Mar 31, 2022-$72.69M–
Q4 FY2021Dec 31, 2021-$40.85M–
Q3 FY2021Sep 30, 2021-$60.96M–

More Zymeworks figures

See a number that looks wrong?